Published today in Clinical Cancer Research, findings from a study led by investigators at the Vall d’Hebron Institute of Oncology (VHIO), which forms part of the Vall d’Hebron Campus, underscore the efficacy of analyzing circulating tumor DNA (ctDNA) using a highly sensitive liquid biopsy platform for evaluating early response, predicting survival and tumor progression in patients with advanced cancers who received treatment with immunotherapy in the context of phase 1 clinical trials.
This article was originally published on MedicalXpress.com

